Evaluation of Endothelin-1 as a Marker of Endothelial Activation in Patients with Sickle Cell Anaemia in a tertiary Hospital in South-South Nigeria
DOI:
https://doi.org/10.4314/ajtmbr.v6i2.3Keywords:
Endothelin-1, Sickle Cell Anaemia, Vaso- Occlusive Crises, Endothelial activationAbstract
Background: Endothelial activation, which often occurs in individuals with sickle cell disease (SCD) patients as a result of oxidative stress, may lead to endothelial dysfunction and acute inflammation. Evaluation of endothelin-1 levels in Vaso occlusive crisis (VOC) may help identify therapeutic targets in the management of SCD.
Materials and Methods: This study aims to assess the role of endothelial activation in the pathophysiology of VOC using endothelin-1 in patients with sickle cell disease managed at the University of Benin Teaching Hospital. This was a longitudinal study conducted at the University of Benin Teaching Hospital, Benin City, Edo State between April 2018 and August 2019. Thirty-five patients with sickle cell anaemia (SCA) were evaluated during VOC and later re-evaluated in steady-state. Thirty-five HbAA subjects, matched for age and sex with the SCA population were recruited as controls. Endothelin -1 (ET- 1) concentrations were determined using an enzyme-linked immunosorbent assay. Data were analyzed using SPSS version 21.
Results: The age range of the SCA patients was 18 – 45 years with a mean SD of 27.7 + 6.7 years. The mean endothelin-1 levels in SCA patients in steady state, VOC and control subjects were 9.35mM, 13.79mM and 4.80mM respectively. The mean ET-1 levels in SCA patients in steady-state and VOC was significantly increased compared to the control subjects (p < 0.001). There was no significant correlation between ET-1 and number of VOCs per year (p = 0.108) and the number of admissions per year (p < 0.005).
Conclusion: SCA is associated with increased endothelial activation which may contribute to the pathogenesis of VOC. This finding may be important in determining the role of the use of anti-inflammatory therapies in the management of SCD.
References
Steinberg MH, Sebastiani P. Genetic modifiers of sickle cell disease. American journal of hematology. 2012 Aug;87(8):795- 803.
Barabino GA, Platt MO, Kaul DK. Sickle cell biomechanics. Annual review of biomedical engineering. 2010 Aug 15;12:345-367.
Steinberg MH. Predicting clinical severity in sickle cell anaemia. British journal of haematology. 2005 May;129(4):465-481.
Herrick JB. Peculiar elongated and sickle- shaped red blood corpuscles in a case of severe anaemia. The Yale Journal of Biology and Medicine 2001; 74:179-184.
Rees DC, Gibson JS. Biomarkers in sickle celldisease. British journal of haematology. 2012 Feb;156(4):433-445.
Rees DC, Williams TN, Gladwin MT. Sickle-cell disease. The Lancet. 2010 Dec 11;376(9757):2018-31.
Jison ML, Munson PJ, Barb JJ, Suffredini AF, Talwar S, Logun C, et al. Blood mononuclear cell gene expression profiles characterize the oxidant, hemolytic, and inflammatory stress of sickle cell disease. Blood. 2004 Jul 1;104(1):270-280.
Jason ML, Munson PJ, Barb JJ, Suffredini AF, Talwar S, Lagun C, Raghavachari N, et al. Blood Mononuclear Cell Gene Expression Profiles Characterize the Oxidant, Hemolytic, and Inflammatory Stress of Sickle Cell Disease. Blood. 2004; Jul 1;
(1). 270 – 280.
van Beers EJ, van Tuijn CF, Mac Gillavry MR, van der Giessen A, Schnog JJ, Biemond BJ, CURAMA Study Group. Sickle cell disease-related organ damage occurs irrespective of pain rate: implications for clinical practice. haematologica. 2008 May 1;93(5):757-760.
Klings ES, Farber HW. Role of free radicals in the pathogenesis of acute chest syndrome in sickle cell disease. Respiratory Research. 2001 Oct;2(5):1-6.
Morris CR, Suh JH, Hagar W, Larkin S, Bland DA, et al. Erythrocyte glutamine depletion, altered redox environment, and pulmonary hypertension in sickle cell disease. Blood, The Journal of the American Society of Hematology. 2008 Jan 1;111(1):402-410.
Noordzij M, Dekker FW, Zoccali C, Jager KJ. Sample Size Calculations. Nephron Clin Pract 2011; 118:319–323.
Dzigba P. Antioxidant status of sickle cell disease children with and without malaria at the korle-bu teaching hospital. July 2013. Thesis/Dissertation submitted to the University of Ghana.
Alagbe AE, Olaniyi JA, Aworanti OW. Adult sickle cell anaemia patients in bone pain crisis have elevated proinflammatory cytokines. Mediterranean journal of haematology and infectious diseases. 2018;10(1).
Graido-Gonzalez E, Doherty JC, Bergreen EW, Organ G, Telfer M, McMillen MA. Plasma endothelin-1, cytokine, and prostaglandin E2 levels in sickle cell disease and acute vaso-occlusive sickle crisis. Blood. 1998; 92:2551–2555.
Rybicki AC, Benjamin LJ. Increased levels of endothelin-1 in plasma of sickle cell anaemia patients. Blood. 1998; 92:2594–2596.
Hammerman SI, Kourembanas S, Conca JJ, Tucci M, Bauer M, Farber HW. Endothelin-1 Production During the Acute Chest Syndrome in Sickle Cell Disease. American Journal of Respiratory and Critical Care Medicine. 1997. 156(1)280-285.
Phelan M, Perrine SP, Brauer M, Faller DV. Sickle erythrocytes, after sickling, regulate the expression of the endothelin-1 gene and protein in human endothelial cells in culture. J Clin Invest. 1995; 96:1145–1151.
Ergul S, Brunson CY, Hutchinson J, Tawfik A, Kutlar A, Webb RC, Ergul A. Vasoactive factors in sickle cell disease: in vitro evidence for endothelin-1 mediated vasoconstriction. American journal of haematology. 2004 Jul;76(3):245-51.
Boric MP, Donoso V, Fournier A, Pierre SS, Huidobro-Toro JP. Endothelin reduces microvascular blood flow by acting on and venules of the hamster cheek pouch. European Journal of pharmacology. 1990;190(1):123–33. https://doi.org
/10.1016/0014-2999 (90)94119-I. [PubMed][Google Scholar]. Accessed November 15, 2019.
Makis AC, Hatzimichael EC, Bourantas KL. The role of cytokines in sickle cell disease. Ann Hematol. 2000 ; 79 ( 8 ) : 407 – 13 . https://doi.org/10.1007/s002770000173. [PubMed] [Google Scholar]. Accessed November 15, 2019.
De Nucci G, Thomas R, D'Orleans-Juste P, Antunes E, Walder C, Warner TD, Vane JR. Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proceedings of the National Academy of Sciences. 1988;85(24):9797–800. https:// doi.org/10.1073/pnas.85.24.9797. [PMC free article] [PubMed] [Google Scholar]. Accessed November 18, 2019.
McMillen MA, Huribal M, Cunningham ME, Kumar R, Sumpio BE. Endothelin-1 increases intracellular calcium in human monocytes and causes the production of interleukin-6. Critical care medicine. 1995 ; 23 ( 1 ) : 34 – 40 . https:// doi. org
/10.1097/00003 246-199501000-00009.[PubMed] [Google Scholar]. Accessed November 15, 2019.
Cunningham ME, Huribal M, Bala R, Mc Millen MA. Endothelin- 1 and endothelin- 4 s t imulate monocyte production of cytokines. Critical care m e d i c i n e . 1 9 9 7 ; 2 5 ( 6 ) : 9 5 8 – 6 4 .https:// doi. org/ 10. 1097/ 00003246- 199706000-00011. [PubMed] [GoogleScholar]. Accessed November 18, 2019.
Wright CD, Cody WL, Dunbar JB, Doherty AM, Hingorani GP, Rapundalo ST. Characterization of endothelins as chemoattractants for human neutrophils. Life sciences. 1994;55(21):1633–41. https://doi.org/10.1016/0024-3205(94) 00330-0. [PubMed] [Google Scholar]. Accessed November 18, 2019.
McCarron RM, Wang L, Stanimirovic DB, Spatz M. Endothelin induction of adhesion molecule expression on human brain m i c r ova s c u l a r e n d o t h e l i a l c e l l s .Neuroscience letters. 1993;156(1):31–4. https://doi.org/10.1016/0304-3940(93) 90432-K. [PubMed] [Google Scholar]. Accessed November 18, 2019.
Sessa WC, Kaw S, Hecker M, Vane JR. The biosynthesis of endothelin-1 by human polymorphonuclear leukocytes. Biochemical and biophysical research communications. 1991;174(2):613–8. https://doi.org/ 10.1016/0006-291X(91) 91461-K. [PubMed][Google Scholar]. Accessed November 18, 2019
Ballas SK, Lieff S, Benjamin LJ, Dampier CD, Heeney MM, et al. Definitions of the phenotypic manifestations of sickle cell disease. Am J Hematol. 2010; 85:6–13. [PMC free article] [PubMed] [Google Scholar]. Accessed November 15, 2019.
Archer N, Galacteros F, Brugnara C. Clinical trials update in sickle cell anaemia. American Journal of Hematology. 2015; 90:934–950. [PMC free article] [PubMed] [Google Scholar]. Accessed November 4, 2019.
Omoti CE. Haematological values in sickle cell anaemia in steady-state and during a vaso- occlusive crisis in Benin City, Nigeria. Annals of African Medicine. 2005;4(2):62-7.
Mombo LE, MabiokoMbembo G, Bisseye C, M b a c k y K , T h i a m F, E d o u A . Haematological values in steady-state sickle cell anaemia patients and matched haemoglobin AA controls in a rural area of Eastern Gabon. Nigerian Postgrad Med J. 2019; 26:13-7.
Hebbel RP, Osarogiagbon R, Kaul D. The endothelial biology of sickle cell disease: inflammation and a chronic vasculopathy. Microcirculation. 2004 Jan 1;11(2):129-151
Kuypers FA. Haemoglobin S polymerization and red cell membrane changes. Hematol Oncol Clin North Am. 2014; 28:155–79
Okpala I. Steady-state platelet count and complications of sickle cell disease. HematolJ. 2002; 3:214–225.
Ataga K, Cappellini MD, Rachmilewitz E. β Thalassaemia and sickle cell anaemia as paradigms of hypercoagulability. Br J Haematol. 2007;139(1):3-13.
Shome DK, Jaradat A, Mahozi AI, Sinan AS, Ebrahim A, Alrahim M, et al. The Platelet Count and its Implications in Sickle Cell Disease Patients Admitted for Intensive Care. Indian Journal of Critical Care Med. 2018;22(8):585–590.
Anea CB, Lyon M, Lee IA, Gonzales JN, Adeyemi A, Falls G, et al. Pulmonary platelet thrombi and vascular pathology in acute chest syndrome in patients with sickle cell disease. Am J Hematol. 2016; 91:173–178.
Gardner K, Thein SL. Super-elevated LDH and thrombocytopenia are markers of a severe subtype of vaso-occlusive crisis in sickle cell disease. Am J Hematol. 2015; 90:206–207.
Shome DK, Ramadorai P, Al-Ajmi A, Ali F, Malik N. Thrombotic microangiopathy in sickle cell disease crisis. Ann Hematol. 2013;92:509–515.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 African Journal of Tropical Medicine and Biomedical Research
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
The data collected from registered and non-registered users of this journal falls within the scope of the standard functioning of peer-reviewed journals. It includes information that makes communication possible for the editorial process; it is used to informs readers about the authorship and editing of content; it enables collecting aggregated data on readership behaviors, as well as tracking geopolitical and social elements of scholarly communication.
This journal’s editorial team uses this data to guide its work in publishing and improving this journal. Data that will assist in developing this publishing platform may be shared with its developer Public Knowledge Project in an anonymized and aggregated form, with appropriate exceptions such as article metrics. The data will not be sold by this journal or PKP nor will it be used for purposes other than those stated here. The authors published in this journal are responsible for the human subject data that figures in the research reported here.
Those involved in editing this journal seek to be compliant with industry standards for data privacy, including the European Union’s General Data Protection Regulation (GDPR) provision for “data subject rights” that include (a) breach notification; (b) right of access; (c) the right to be forgotten; (d) data portability; and (e) privacy by design. The GDPR also allows for the recognition of “the public interest in the availability of the data,” which has a particular saliency for those involved in maintaining, with the greatest integrity possible, the public record of scholarly publishing.
